Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency

Alan Barker, I. Iwata-Morgan, L. Oveson, R. Roussel

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objectives: To ascertain how long 120 mg/kg alpha1-antitrypsin concentrate (α1-AT-C), administered IV every 2 weeks, can maintain α1- antitrypsin (α1-AT) serum levels above 70 to 80 mg/dL. Secondary objectives were to summarize the nature, severity, and relationship of a plasma-derived α1-AT-C infusion to any side effects. Methods: This was an open-label uncontrolled pharmacokinetic study. α1-AT-C was administered IV every 2 weeks for 10 infusions in 23 patients with PIZ α1-AT deficiency. Serum α1-AT levels and neutralizing elastase activity were measured preinfusion, postinfusion, and at nadir. During two infusion periods, daily serum α1-AT and neutralizing elastase activities were measured on the seventh to 14th days. Five patients received BAL assays for α1-AT and neutralizing elastase activity. Adverse events were recorded in a patient diary and by a nurse at each infusion visit. Results: The 120-mg/kg dose of α1-AT-C could not maintain nadir serum protective levels above 70 or 80 mg/dL for the entire 14-day dosing interval in most patients. None of the patients had α1-AT levels above 80 mg/dL for all 14 days. The serum α1-AT and neutralizing elastase levels correlated suggesting functional activity. The BAL α1-AT and neutralizing elastase activities were low and did not correlate with serum levels. Conclusion: α1-AT-C at 120 mg/kg administered every 2 weeks did not maintain nadir serum α1-AT levels above 70 to 80 mg/dL for a 14- day dosing interval. Higher doses every 2 weeks or decreased interval between infusions may be required.

Original languageEnglish (US)
Pages (from-to)607-613
Number of pages7
JournalChest
Volume112
Issue number3
StatePublished - 1997

Fingerprint

Pancreatic Elastase
Pharmacokinetics
Serum
Dimercaprol
Nurses

Keywords

  • α-antitrypsin
  • Protease inhibitors
  • Pulmonary emphysema

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Barker, A., Iwata-Morgan, I., Oveson, L., & Roussel, R. (1997). Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency. Chest, 112(3), 607-613.

Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency. / Barker, Alan; Iwata-Morgan, I.; Oveson, L.; Roussel, R.

In: Chest, Vol. 112, No. 3, 1997, p. 607-613.

Research output: Contribution to journalArticle

Barker, A, Iwata-Morgan, I, Oveson, L & Roussel, R 1997, 'Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency', Chest, vol. 112, no. 3, pp. 607-613.
Barker A, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency. Chest. 1997;112(3):607-613.
Barker, Alan ; Iwata-Morgan, I. ; Oveson, L. ; Roussel, R. / Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency. In: Chest. 1997 ; Vol. 112, No. 3. pp. 607-613.
@article{06248c2fe56e41b2a8335eaecc55e95c,
title = "Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency",
abstract = "Objectives: To ascertain how long 120 mg/kg alpha1-antitrypsin concentrate (α1-AT-C), administered IV every 2 weeks, can maintain α1- antitrypsin (α1-AT) serum levels above 70 to 80 mg/dL. Secondary objectives were to summarize the nature, severity, and relationship of a plasma-derived α1-AT-C infusion to any side effects. Methods: This was an open-label uncontrolled pharmacokinetic study. α1-AT-C was administered IV every 2 weeks for 10 infusions in 23 patients with PIZ α1-AT deficiency. Serum α1-AT levels and neutralizing elastase activity were measured preinfusion, postinfusion, and at nadir. During two infusion periods, daily serum α1-AT and neutralizing elastase activities were measured on the seventh to 14th days. Five patients received BAL assays for α1-AT and neutralizing elastase activity. Adverse events were recorded in a patient diary and by a nurse at each infusion visit. Results: The 120-mg/kg dose of α1-AT-C could not maintain nadir serum protective levels above 70 or 80 mg/dL for the entire 14-day dosing interval in most patients. None of the patients had α1-AT levels above 80 mg/dL for all 14 days. The serum α1-AT and neutralizing elastase levels correlated suggesting functional activity. The BAL α1-AT and neutralizing elastase activities were low and did not correlate with serum levels. Conclusion: α1-AT-C at 120 mg/kg administered every 2 weeks did not maintain nadir serum α1-AT levels above 70 to 80 mg/dL for a 14- day dosing interval. Higher doses every 2 weeks or decreased interval between infusions may be required.",
keywords = "α-antitrypsin, Protease inhibitors, Pulmonary emphysema",
author = "Alan Barker and I. Iwata-Morgan and L. Oveson and R. Roussel",
year = "1997",
language = "English (US)",
volume = "112",
pages = "607--613",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic study of α1-antitrypsin infusion in α1-antitrypsin deficiency

AU - Barker, Alan

AU - Iwata-Morgan, I.

AU - Oveson, L.

AU - Roussel, R.

PY - 1997

Y1 - 1997

N2 - Objectives: To ascertain how long 120 mg/kg alpha1-antitrypsin concentrate (α1-AT-C), administered IV every 2 weeks, can maintain α1- antitrypsin (α1-AT) serum levels above 70 to 80 mg/dL. Secondary objectives were to summarize the nature, severity, and relationship of a plasma-derived α1-AT-C infusion to any side effects. Methods: This was an open-label uncontrolled pharmacokinetic study. α1-AT-C was administered IV every 2 weeks for 10 infusions in 23 patients with PIZ α1-AT deficiency. Serum α1-AT levels and neutralizing elastase activity were measured preinfusion, postinfusion, and at nadir. During two infusion periods, daily serum α1-AT and neutralizing elastase activities were measured on the seventh to 14th days. Five patients received BAL assays for α1-AT and neutralizing elastase activity. Adverse events were recorded in a patient diary and by a nurse at each infusion visit. Results: The 120-mg/kg dose of α1-AT-C could not maintain nadir serum protective levels above 70 or 80 mg/dL for the entire 14-day dosing interval in most patients. None of the patients had α1-AT levels above 80 mg/dL for all 14 days. The serum α1-AT and neutralizing elastase levels correlated suggesting functional activity. The BAL α1-AT and neutralizing elastase activities were low and did not correlate with serum levels. Conclusion: α1-AT-C at 120 mg/kg administered every 2 weeks did not maintain nadir serum α1-AT levels above 70 to 80 mg/dL for a 14- day dosing interval. Higher doses every 2 weeks or decreased interval between infusions may be required.

AB - Objectives: To ascertain how long 120 mg/kg alpha1-antitrypsin concentrate (α1-AT-C), administered IV every 2 weeks, can maintain α1- antitrypsin (α1-AT) serum levels above 70 to 80 mg/dL. Secondary objectives were to summarize the nature, severity, and relationship of a plasma-derived α1-AT-C infusion to any side effects. Methods: This was an open-label uncontrolled pharmacokinetic study. α1-AT-C was administered IV every 2 weeks for 10 infusions in 23 patients with PIZ α1-AT deficiency. Serum α1-AT levels and neutralizing elastase activity were measured preinfusion, postinfusion, and at nadir. During two infusion periods, daily serum α1-AT and neutralizing elastase activities were measured on the seventh to 14th days. Five patients received BAL assays for α1-AT and neutralizing elastase activity. Adverse events were recorded in a patient diary and by a nurse at each infusion visit. Results: The 120-mg/kg dose of α1-AT-C could not maintain nadir serum protective levels above 70 or 80 mg/dL for the entire 14-day dosing interval in most patients. None of the patients had α1-AT levels above 80 mg/dL for all 14 days. The serum α1-AT and neutralizing elastase levels correlated suggesting functional activity. The BAL α1-AT and neutralizing elastase activities were low and did not correlate with serum levels. Conclusion: α1-AT-C at 120 mg/kg administered every 2 weeks did not maintain nadir serum α1-AT levels above 70 to 80 mg/dL for a 14- day dosing interval. Higher doses every 2 weeks or decreased interval between infusions may be required.

KW - α-antitrypsin

KW - Protease inhibitors

KW - Pulmonary emphysema

UR - http://www.scopus.com/inward/record.url?scp=0030610568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030610568&partnerID=8YFLogxK

M3 - Article

C2 - 9315791

AN - SCOPUS:0030610568

VL - 112

SP - 607

EP - 613

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -